Do Wall Street Analysts Like Bio-Techne Stock?

Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. With a market cap of $7.7 billion, Bio-Techne operates through the Protein Sciences and Diagnostics and Genomics segments.

Shares of TECH have significantly lagged behind the broader market over the past 52 weeks. TECH stock has dropped 40.7% over this period, while the broader S&P 500 Index ($SPX) has gained 12.5%. Moreover, shares of TECH are down 31.8% on a YTD basis, compared to SPX’s 1.3% return.